Modified release tizanidine: a review

Area of Science:

• Pharmacology
• Neurology
• Drug Development

Background:

• Conventional tizanidine tablets effectively relieve spasticity but require frequent dosing due to a short half-life.
• A modified-release (MR) formulation of tizanidine has been developed to enable once-daily administration.
• Understanding the pharmacokinetic and clinical profile of MR tizanidine is crucial for optimizing spasticity management.

Purpose of the Study:

• To review the pharmacokinetic and clinical properties of a modified-release formulation of tizanidine.
• To evaluate the efficacy and safety of once-daily MR tizanidine in spastic patients.
• To compare the bioavailability of MR tizanidine with conventional tizanidine tablets.

Main Methods:

• Pharmacokinetic studies (single- and multiple-dose) in healthy volunteers.
• Clinical trials assessing spasticity and disability in patients.
• Evaluation of adverse effects and tolerability.

Main Results:

• MR tizanidine demonstrated bioavailability comparable to conventional tablets, unaffected by food.
• Significant improvements in spasticity (94%) and disability (79%) were observed in patients treated with MR tizanidine.
• Adverse effects occurred in approximately 33% of patients, primarily mild, transient muscular weakness, rarely requiring treatment discontinuation.

Conclusions:

• Modified-release tizanidine provides an effective and convenient once-daily therapeutic option for managing spasticity.
• The MR formulation is well-tolerated, with a favorable safety profile.
• MR tizanidine offers a significant improvement over conventional formulations, enhancing patient compliance and potentially improving outcomes.